Le Lézard
Classified in: Health
Subject: NEW PRODUCTS/SERVICES

Jushi Holdings Inc. Opens 27th Nationwide Dispensary, 17th BEYOND / HELLOtm Retail Location in Pennsylvania and Third Store in the Greater Pittsburgh Region through its Subsidiary, Franklin Bioscience - SW LLC


BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. ("Jushi" or the "Company") (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced the opening of its 27th nationwide dispensary, 17th BEYOND / HELLOtm dispensary in Pennsylvania and third store in the Greater Pittsburgh Region through its subsidiary, Franklin Bioscience - SW LLC. BEYOND / HELLOtm Pittsburgh will begin serving Pennsylvania medical marijuana patients and caregivers on Wednesday, December 15, 2021 at 10:00 a.m., providing an unparalleled in-store experience, convenient online reservations available through beyond-hello.com and in-store express pickup.

BEYOND / HELLOtm Pittsburgh, located at 2009 E. Carson St. in the Mt. Oliver Borough of Pittsburgh, is a community that has its own unique sense of pride and independence deeply rooted in its history that combines the old and new, of urban and suburban. BEYOND / HELLO's new storefront features plenty of on-site parking and is located in the center of the main entertainment district in the South Side of the city. Boutiques, restaurants, art galleries, theater and live music venues are all within walking distance. It is also centrally located within minutes of the Phipps Conservatory, the Botanical Gardens and the Steel City's Shopping District. This dispensary will serve customers Monday through Saturday from 9:00 a.m. to 8:00 p.m. and on Sunday from 10:00 a.m. to 6:00 p.m., and joins the Company's Greater Pittsburgh locations: BEYOND / HELLOtm Irwin and BEYOND / HELLOtm Johnstown.

"As a core market for Jushi, we continue to be strategic and aggressive with our retail strategy, product launches as well as cultivation and manufacturing expansion plans in Pennsylvania," said Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi. "Since acquiring Franklin Bioscience-Penn LLC and its subsidiaries in 2019, we've grown the number of Pennsylvania BEYOND / HELLOtm stores from two to 17, built a loyal patient base, introduced a suite of highly innovative branded products and assembled an exceptionally talented retail team. Our 17th medical marijuana dispensary in Pennsylvania and third in the Greater Pittsburgh Region is well positioned to service the Commonwealth's growing number of medical marijuana patients and caregivers."

BEYOND / HELLOtm Pittsburgh will provide customers with an efficient, accessible, and safe experience that goes beyond the traditional cannabis retail environment. As part of this commitment to exceeding patients' expectations, a licensed pharmacist, along with experienced well-trained staff, will also be on-site to dispense products, answer questions and provide service to patients and caregivers. The dispensary will carry dry leaf, concentrates, cartridges, tinctures, topicals, capsules, pills and various ancillary products such as approved batteries and devices. In addition, BEYOND / HELLOtm Pittsburgh is handicap accessible and LGBTQIA+ friendly. 

About Jushi Holdings Inc.
We are a vertically integrated cannabis company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, visit jushico.com or BEYOND / HELLOtm on Instagram and Facebook.

Forward-Looking Information and Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, involve estimates, projections, plans, goals, forecasts, and assumptions that may prove to be inaccurate. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases or may contain statements that certain actions, events or results "may," "could," "would," "might" or "will be taken," "will continue," "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include but are not limited to, information concerning the expectations regarding Jushi, or the ability of Jushi to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has certain expectations and has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward- looking information and statements are the following: the ability of Jushi to successfully and/or timely achieve business objectives, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; and compliance with extensive government regulation, as well as other risks and uncertainties which are more fully described in the Company's Management, Discussion and Analysis for the three months ended September 30, 2021, and other filings with securities and regulatory authorities which are available at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward- looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward- looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

For further information, please contact:

Investor Relations Contact:
Michael Perlman
Executive Vice President of Investor Relations
561-281-0247
[email protected]

Media Contact:
Ellen Mellody
570-209-29 47
[email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/42595fd7-0feb-470d-a887-47f10f52ca7f

https://www.globenewswire.com/NewsRoom/AttachmentNg/a068ce65-4c1c-43c1-b2d2-3d594b07ceb5



These press releases may also interest you

at 11:56
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....

at 11:16
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...

at 11:15
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...



News published on and distributed by: